News Archive
| 2025 | ||
|---|---|---|
| Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program | June 16, 2025 | view |
| Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025 | June 2, 2025 | view |
| Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T® Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer | May 30, 2025 | view |
| Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting | May 23, 2025 | view |
| Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025 | April 25, 2025 | view |
| Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies | March 25, 2025 | view |
| 2024 | ||
|---|---|---|
| Syncromune to Present at Piper Sandler 36th Annual Healthcare Conference | December 2, 2024 | view |
| Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | July 1, 2024 | view |
| Syncromune® Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer | May 30, 2024 | view |
| Syncromune® Inc. Presents Positive Results from SYNC-T SV-102 Phase 1 Trial at AACR Annual Meeting 2024 | April 8, 2024 | view |
| Syncromune® Inc. to Present Initial Clinical Data from SYNC-T SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024 | March 6, 2024 | view |
| 2023 | ||
|---|---|---|
| Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D. | October 31, 2023 | view |
| Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies | August 30, 2023 | view |
| Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical Officer | July 12, 2023 | view |
| 2024 | |
|---|---|
| Syncromune to Present at Piper Sandler 36th Annual Healthcare Conference | December 2, 2024 |
| Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | July 1, 2024 |
| Syncromune® Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer | May 30, 2024 |
| Syncromune® Inc. Presents Positive Results from SYNC-T SV-102 Phase 1 Trial at AACR Annual Meeting 2024 | April 8, 2024 |
| Syncromune® Inc. to Present Initial Clinical Data from SYNC-T SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024 | March 6, 2024 |
| 2023 | |
|---|---|
| Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D. | October 31, 2023 |
| Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies | August 30, 2023 |
| Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical Officer | July 12, 2023 |
| 2022 | |
|---|---|
| Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Combination Immunotherapy Platform | October 18, 2022 |
| Syncromune, Inc. to Present at 2022 BIO CEO & Investor Conference | February 12, 2022 |
| 2022 | ||
|---|---|---|
| Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Combination Immunotherapy Platform | October 18, 2022 | view |
| Syncromune, Inc. to Present at 2022 BIO CEO & Investor Conference | February 12, 2022 | view |
